摘要
Stimulator of interferon genes (STING) agonists rapidly moved into clinical trials with great optimism but have only shown mediocre therapeutic efficacy in patients. Li and colleagues revealed that STING activation in B cells drives immunosuppression that counteracts the stimulatory activity of these drugs, and that blocking regulatory B-cell function can improve STING-based cancer immunotherapy. Using specific deletion of STING (TMEM173) in B cells, they first showed that systemic delivery of STING agonists is more effective in controlling multiple cancer models, most importantly pancreatic ductal adenocarcinomas (PDAC). Next, they found that in response to STING activation, B cells take on a regulatory phenotype and produce two suppressive cytokines, IL35 and IL10. They found that IL35 production is essential for their suppressive nature, acting to suppress natural killer (NK) cell antitumor responses specifically in response to STING agonists. Finally, they showed that a combination of blocking anti-IL35 antibodies in combination with STING agonists leads to effective control of mouse models of PDAC and lung cancer and that PDAC patients, compared with healthy donors, exhibited elevated induction of IL35 in response to STING agonists.Expert Commentary: A combination of STING agonists with anti-IL35 blockade diminishes B-regulatory function and enhances NK-cell antitumor responses.Li S, Mirlekar B, Johnson BM, Brickey WJ, Wrobel JA, Yang N, et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 2022;610:373-80.Despite the key role of metastasis in cancer-related mortality, no recurrent metastasis-specific mutations have previously been identified. Rahrmann and colleagues discovered that the sodium leak channel nonselective protein (NALCN) is frequently mutated in cancer, leading to metastases. Pathogenic NALCN alterations were observed commonly in gastric, colorectal, lung, prostate, and head and neck cancers. Genetic or pharmacologic inhibition of NALCN led to increased circulating tumor cells and metastasis in multiple tumor types in vivo but did not modify primary tumor incidence or proliferation. Remarkably, NALCN inhibition increased normal epithelia cell shedding and led to the formation of ectopic structures in normal tissues.Expert Commentary: This study has identified the first recurrent metastasis-specific mutation and suggests a possible new pathway for targeting metastasis.Rahrmann EP, Shorthouse D, Jassim A, Hu LP, Ortiz M, Mahler-Araujo B, et al. The NALCN channel regulates metastasis and nonmalignant cell dissemination. Nature Genetics; Published September 29, 2022; doi: 10.1038/s41588-022-01182-0.CAR T therapy of acute myeloid leukemia (AML) remains challenging given significant overlap of target antigens with normal hematopoietic cells. Le and colleagues used xenotransplantation and an innovative ex vivo endothelial cell coculture system to model high-risk infant/childhood acute megakaryoblastic leukemia driven by the fusion oncoprotein CBFA2T3-GLIS2 (C/G). Interrogating transcriptomes of C/G cells, the authors identified six plasma membrane proteins in C/G leukemic cells that were silent in normal hematopoiesis. FOLR1 (folate receptor alpha) was prioritized as a known target in solid cancers. The authors developed a FOLR1-directed CAR T for C/G AML and showed that FOLR1 CAR T cells were effective at eliminating primary C/G-positive AML cells in vitro and in vivo. Further on-target and off-target evaluation is now warranted.Expert Commentary: Although FOLR1 is expressed in other healthy tissues, its absence from normal hemopoietic cells presents promise as a CAR T therapy in pediatric C/G AML, a subgroup with dismal prognosis.Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, et al. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. Journal of Clinical Investigation; Published September 22, 2022; doi: 10.1172/JCI157101.Neuroblastoma is a cold tumor, and immunotherapy has had little clinical success except for the use of anti-GD2 antibodies. Sengupta and colleagues analyzed transcripts involved in both immune activation as well as evasion by performing bulk single-cell RNA sequencing of human neuroblastoma tumors across multiple subtypes. After identifying a subset of immunogenic tumors, the authors performed further characterization and determined these tumors were more mesenchymal as compared with adrenergic. The authors also found that during the process of reprogramming between these lineages, the expression of immune genes was altered via epigenetic regulation. T-cell infiltration into the tumor was stimulated by cells expressing a mesenchymal signature, and checkpoint blockade immunotherapy was effective in inducing T-cell cytotoxicity against these mesenchymal tumors.Expert Commentary: This study describes differences in immunogenic potential between mesenchymal versus adrenergic neuroblastoma lineage, which dictates the efficacy of immunotherapy.Sengupta S, Das S, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, et al. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nat Cancer 2022;3:1228-46.Despite advances in other tumor entities, immunotherapies have a limited effect in glioblastoma (GBM). A potential role of myeloid-derived suppressor cells (MDSC) in promoting treatment resistance suggests MDSCs as next-generation immunotherapy targets. MDSCs consist of two distinct subsets, granulocytic/polymorphonuclear (gMDSC) and monocytic (mMDSC). mMDSCs characteristically drive progression of GBM in preclinical models to a greater extent than gMDSCs. ATAC-seq performed on mMDSCs and gMDSCs isolated from the bone marrow of GL261-bearing or control mice indicated that mMDSCs and gMDSCs have distinct chromatin accessibility signatures. mMDSCs have higher integrin β1 and DPP-4 expression, which has functional consequences on the tumor-immune microenvironment. Blockade of integrin β1 abrogated the tumor-promoting phenotype of mMDSCs and altered the immune profile in the tumor microenvironment, while treatment with a DPP-4 inhibitor extended survival in preclinical GBM models.Expert Commentary: The current results demonstrate that integrin β1 and related DPP-4 signaling contribute to mMDSC function in GBM and highlight the potential of cell adhesion programming as a therapeutic target in GBM.Bayik D, Bartels CF, Lovrenert K, Watson DC, Zhang D, Kay K, et al. Distinct cell adhesion signature defines glioblastoma myeloid-derived suppressor cell subsets. Cancer Res 2022; 82:4274–87.The Hedgehog signaling pathway is central to proper patterning and proliferation in multiple developing tissues and persists in many adult stem cell types. Disruption of this pathway, often at the level of mutations in the membrane proteins PATCHED and SMOOTHENED, is seen in skin and brain tumors. However, how activation of SMOOTHENED leads to modulation of Hedgehog-dependent transcription factors is not fully understood. Using purified protein, cell-based systems, and model organisms, Happ and colleagues identified a sequence in the proximal C terminus of SMOOTHENED that interacted directly with PKA-C and acted as a pseudosubstrate. When SMOOTHENED was in its active conformation, this region inhibited PKA-C catalytic activity and thus freed GLI transcription factors from inhibitory phosphorylation, ultimately enabling Hedgehog-dependent transcriptional programs. Additional data suggests this “nonstandard” mechanism may also be at work downstream of another key morphogen, Wnt.Expert Commentary: Elucidation of the biochemical details of interactions between PKA-C and SMOOTHENED highlight a potential new point for pharmacological modulation of such pathways in the lab and clinic.Happ JT, Arveseth CD, Bruystens J, Bertinetti D, Nelson IB, Olivieri C, et al. A PKA inhibitor motif within SMOOTHENED controls Hedgehog signal transduction. Nature Struct Mol Biol 2022;29:990-9.Note: Breaking Insights are written by Cancer Research editors. Readers are encouraged to consult the articles referred to in each item for full details on the findings described.